Please assess the completion status of the following clinical trial:

Trial Title: Dexlansoprazole MR-Based Concomitant Quadruple Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~H. pylori-infected outpatients with endoscopically proven peptic ulcer diseases or gastritis.~Exclusion Criteria:~1. Previous H. pylori-eradication therapy~2. ingestion of antibiotics, bismuth, or PPIs within the prior 4 weeks~3. patients with allergic history to the medications used~4. patients with previous gastric surgery~5. the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)~6. pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR group (Type: EXPERIMENTAL): Dexlansoprazole MR 60 mg qd.,clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
- lansoprazole group (Type: EXPERIMENTAL): Lansoprazole 30 mg bid., clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).